Polyarticular Juvenile Idiopathic Arthritis
8
2
2
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
25%
2 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (8)
Tenosynovitis in Polyarticular and Oligoarticular Juvenile Idiopathic Arthritis
Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis
Comparative Study of Leflunomide Plus Methotrexate Versus Methotrexate Monotherapy in Refractory Polyarticular Juvenile Idiopathic Arthritis Patients
Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases
An Observational Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Pediatric Participants With Polyarticular Juvenile Idiopathic Arthritis (pJIA)
Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS
Surveillance of Humira in Korean JIA Patients
Long-term Treatment Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)